Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: A meta-analysis

AIDS

Volumn 30, Issue 2, 2016, Pages 273-291

  Park, Lesley S ^a   Hernandez Ramirez, Raul U ^b   Silverberg, Michael J ^c   Crothers, Kristina ^d   Dubrow, Robert ^b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DIVISION OF RESEARCH   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Acquired immunodeficiency syndrome; Cancer prevention; Cancer risk factors; High income countries; HIV infections; Neoplasms

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALCOHOL CONSUMPTION; ARTICLE; CANCER RISK; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MEDLINE; META ANALYSIS; OBESITY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; UNITED STATES; VIRUS TRANSMISSION; ADULT; ADVERSE EFFECTS; COMPLICATION; DEVELOPED COUNTRY; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS, CHRONIC; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RISK ASSESSMENT; RISK FACTOR;

ADULT; DEVELOPED COUNTRIES; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS, CHRONIC; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; SMOKING;

EID: 84952929216     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000922     Document Type: Article

References (199)

1. Morlat P, Roussillon C, Henard S, Salmon D, Bonnet F, Cacoub P, et al. Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000. AIDS 2014; 28:1181-1191.
2. Smith CJ, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet 2014; 384:241-248.
3. Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med 2013; 14:195-207.
4. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387-1396.
5. Calabresi A, Ferraresi A, Festa A, Scarcella C, Donato F, Vassallo F, et al. Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of Northern Italy, 1999-2009. HIV Med 2013; 14:481-490.
6. Dubrow R, Silverberg MJ, Park LS, Crothers K, Justice AC. HIV infection, aging, and immune function: implications for cancer risk and prevention. Curr Opin Oncol 2012; 24:506-516.
7. Park LS, Tate JP, Rodriguez Barradas M, Rimland D, Goetz MB, Gibert C, et al. Cancer incidence in HIV-infected versus uninfected veterans: comparison of cancer registry and ICD-9 code diagnoses. J AIDS Clin Res 2014; 5:318.
8. Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009; 52:611-622.
9. Gopal S, Achenbach CJ, Yanik EL, Dittmer DP, Eron JJ, Engels EA. Moving forward in HIV-associated cancer. J Clin Oncol 2014; 32:876-880.
10. Hleyhel M, Bouvier AM, Belot A, Tattevin P, Pacanowski J, Genet P, et al. Risk of non-AIDS-defining cancers among HIV-1-infected individuals in France between 1997 and 2009: results from a French cohort. AIDS 2014; 28:2109-2118.
11. Hleyhel M, Belot A, Bouvier AM, Tattevin P, Pacanowski J, Genet P, et al. Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis 2013; 57:1638-1647.
12. Chaturvedi AK, Madeleine MM, Biggar RJ, Engels EA. Risk of human papillomavirus-associated cancers among persons with AIDS. J Natl Cancer Inst 2009; 101:1120-1130.
13. Silverberg MJ, Leyden W, Warton EM, Quesenberry CP Jr, Engels EA, Asgari MM. HIV infection status, immunodeficiency, and the incidence of non-melanoma skin cancer. J Natl Cancer Inst 2013; 105:350-360.
14. Grulich AE, Jin F, Poynten IM, Vajdic CM. HIV, cancer, and aging. Sex Health 2011; 8:521-525.
15. Engels EA. Non-AIDS-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities. AIDS 2009; 23:875-885.
16. Borges AH, Dubrow R, Silverberg MJ. Factors contributing to risk for cancer among HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will alter this risk. Curr Opin HIV AIDS 2014; 9:34-40.
17. Rubinstein PG, Aboulafia DM, Zloza A. Malignancies in HIV/AIDS: from epidemiology to therapeutic challenges. AIDS 2014; 28:453-465.
18. United States Public Health Service Office of the Surgeon General, National Center for Chronic Disease Prevention and Health Promotion (U.S.). The health consequences of smoking: a report of the Surgeon General, 2004. http://www. cdc.gov/tobacco/data-statistics/sgr/2004/complete-report/index. htm. [Accessed 25 February 2015]
19. Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve P. Smoking and colorectal cancer: a metaanalysis. JAMA 2008; 300:2765-2778.
20. Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M, et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case-control study. J Natl Cancer Inst 2011; 103:1686-1695.
21. Leonardi-Bee J, Ellison T, Bath-Hextall F. Smoking and the risk of nonmelanoma skin cancer: systematic review and metaanalysis. Arch Dermatol 2012; 148:939-946.
22. Boffetta P, Hashibe M. Alcohol and cancer. Lancet Oncol 2006; 7:149-156.
23. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4:579-591.
24. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Washington, DC: AICR; 2007.
25. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Bodymass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371:569-578.
26. Trottier H, Burchell AN. Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics 2009; 12:291-307.
27. Iannacone MR, Gheit T, Waterboer T, Giuliano AR, Messina JL, Fenske NA, et al. Case-control study of cutaneous human papillomaviruses in squamous cell carcinoma of the skin. Cancer Epidemiol Biomarkers Prev 2012; 21:1303-1313.
28. Bouwes Bavinck JN, Neale RE, Abeni D, Euvrard S, Green AC, Harwood CA, et al. Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma. Cancer Res 2010; 70:9777-9786.
29. Feltkamp MC, de Koning MN, Bavinck JN, Ter Schegget J. Betapapillomaviruses: innocent bystanders or causes of skin cancer. J Clin Virol 2008; 43:353-360.
30. Li X, Gao L, Li H, Gao J, Yang Y, Zhou F, et al. Human papillomavirus infection and laryngeal cancer risk: a systematic review and meta-analysis. J Infect Dis 2013; 207:479-488.
31. Anantharaman D, Gheit T, Waterboer T, Abedi-Ardekani B, Carreira C, McKay-Chopin S, et al. Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study. J Natl Cancer Inst 2013; 105:536-545.
32. Guo F, Liu Y, Wang X, He Z, Weiss NS, Madeleine MM, et al. Human papillomavirus infection and esophageal squamous cell carcinoma: a case-control study. Cancer Epidemiol Biomarkers Prev 2012; 21:780-785.
33. Sitas F, Egger S, Urban MI, Taylor PR, Abnet CC, Boffetta P, et al. InterSCOPE study: associations between esophageal squamous cell carcinoma and human papillomavirus serological markers. J Natl Cancer Inst 2012; 104:147-158.
34. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142:1264-1273.e1.
35. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45:529-538.
36. Negri E, Little D, Boiocchi M, La Vecchia C, Franceschi S. B-cell non-Hodgkin's lymphoma and hepatitis C virus infection: a systematic review. Int J Cancer 2004; 111:1-8.
37. Nath A, Agarwal R, Malhotra P, Varma S. Prevalence of hepatitis B virus infection in non-Hodgkin lymphoma: a systematic review and meta-analysis. Intern Med J 2010; 40:633-641.
38. Division of Health Interview Statistics. About the National Health Interview Survey. http://www.cdc.gov/nchs/nhis/about-nhis.htm. [Accessed 25 February 2015]
39. Schoenborn CA, Adams PF. Health behaviors of adults: United States, 2005-2007. National Center for Health Statistics. Vital Health Stat 2010; 10 (No. 245):1-132.
40. Division of Health Interview Statistics. About the National Health and Nutrition Examination Survey. http://www.cdc. gov/nchs/nhanes/about-nhanes.htm. [Accessed 25 February 2015]
41. Huffman MD, Capewell S, Ning H, Shay CM, Ford ES, Lloyd-Jones DM. Cardiovascular health behavior and health factor changes (1988-2008) and projections to 2020: results from the National Health and Nutrition Examination Surveys. Circulation 2012; 125:2595-2602.
42. Guenther PM, Ding EL, Rimm EB. Alcoholic beverage consumption by adults compared to dietary guidelines: results of the National Health and Nutrition Examination Survey, 2009-2010. J Acad Nutr Diet 2013; 113:546-550.
43. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303:235-241.
44. Steinau M, Hariri S, Gillison ML, Broutian TR, Dunne EF, Tong ZY, et al. Prevalence of cervical and oral human papillomavirus infections among US women. J Infect Dis 2014; 209:1739-1743.
45. Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health and Nutrition Examination Survey, 2003-2006. J Infect Dis 2011; 204:566-573.
46. Gillison ML, Broutian T, Pickard RK, Tong ZY, Xiao W, Kahle L, et al. Prevalence of oral HPV infection in the United States, 2009-2010. JAMA 2012; 307:693-703.
47. Chaturvedi AK, Graubard BI, Pickard RK, Xiao W, Gillison ML. High-risk oral human papillomavirus load in the US population, National Health and Nutrition Examination Survey 2009-2010. J Infect Dis 2014; 210:441-447.
48. Ditah I, Ditah F, Devaki P, Ewelukwa O, Ditah C, Njei B, et al. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol 2014; 60:691-698.
49. Ioannou GN. Hepatitis B virus in the United States: infection, exposure, and immunity rates in a nationally representative survey. Ann Intern Med 2011; 154:319-328.
50. Behavioral Risk Factor Surveillance System. About BRFSS. http://www.cdc.gov/brfss/about/index.htm. [Accessed 25 February 2015]
51. Kahende J, Teplinskaya A, Malarcher A, Husten C, Maurice E. State-specific prevalence of cigarette smoking among adults and quitting among persons aged 18-35 years-United States, 2006. MMWR Morb Mortal Wkly Rep 2007; 56:993-996.
52. Paul LA, Grubaugh AL, Frueh BC, Ellis C, Egede LE. Associations between binge and heavy drinking and health behaviors in a nationally representative sample. Addict Behav 2011; 36:1240-1245.
53. McQuillan GM, Kruszon-Moran D, Granade T, Feldman JW. Seroprevalence of HIV in the US household population aged 18-49 years: The National Health and Nutrition Examination Surveys, 1999-2006. J Acquir Immune Defic Syndr 2010; 53:117-123.
54. Nyaga V, Arbyn M, Aerts M. METAPROP: Stata module to perform fixed and random effects meta-analysis of proportions, 2014. http://ideas.repec.org/c/boc/bocode/s457781.html. [Accessed 25 February 2015]
55. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327:557-560.
56. Barendregt JJ, Doi SA, Lee YY, Norman RE, Vos T. Metaanalysis of prevalence. J Epidemiol Community Health 2013; 67:974-978.
57. Freeman MF, Tukey JW. Transformations related to the angular and the square root. Ann Math Statist 1950; 21:607-611.
58. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
59. Riley RD, Higgins JP, Deeks JJ. Interpretation of random effects meta-analyses. BMJ 2011; 342:d549.
60. Anzures-Cabrera J, Higgins JP. Graphical displays for metaanalysis: An overview with suggestions for practice. Res Synth Methods 2010; 1:66-80.
61. Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ 1997; 315:629-634.
62. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50:1088-1101.
63. Baum MK, Sales S, Jayaweera DT, Lai S, Bradwin G, Rafie C, et al. Coinfection with hepatitis C virus, oxidative stress and antioxidant status in HIV-positive drug users in Miami. HIV Med 2011; 12:78-86.
64. Briongos Figuero LS, Bachiller Luque P, Palacios Martn T, González Sagrado M, Eiros Bouza JM. Assessment of factors influencing health-related quality of life in HIV-infected patients. HIV Med 2011; 12:22-30.
65. Broom J, Sowden D, Williams M, Taing K, Morwood K, McGill K. Moving from viral suppression to comprehensive patientcentered care: the high prevalence of comorbid conditions and health risk factors in HIV-1-infected patients in Australia. J Int Assoc Physicians AIDS Care 2012; 11:109-114.
66. Broyles LM, Gordon AJ, Sereika SM, Ryan CM, Erlen JA. Predictive utility of brief Alcohol Use Disorders Identification Test (AUDIT) for human immunodeficiency virus antiretroviral medication nonadherence. Subst Abus 2011; 32:252-261.
67. Bryant VE, Kahler CW, Devlin KN, Monti PM, Cohen RA. The effects of cigarette smoking on learning and memory performance among people living with HIV/AIDS. AIDS Care 2013; 25:1308-1316.
68. Capili B, Anastasi JK, Ogedegbe O. HIV and general cardiovascular risk. J Assoc Nurses AIDS Care 2011; 22:362-375.
69. Cervero M, Agud JL, Garcá-Lacalle C, Alcazár V, Torres R, Jusdado JJ, et al. Prevalence of vitamin D deficiency and its related risk factor in a Spanish cohort of adult HIV-infected patients: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2012; 28:963-971.
70. Chander G, Stanton C, Hutton HE, Abrams DB, Pearson J, Knowlton A, et al. Are smokers with HIV using information and communication technology? Implications for behavioral interventions. AIDS Behav 2012; 16:383-388.
71. Collazos J, Cartón JA, Asensi V. Gender differences in liver fibrosis and hepatitis C virus-related parameters in patients coinfected with human immunodeficiency virus. Curr HIV Res 2011; 9:339-345.
72. Fabbiani M, Ciccarelli N, Tana M, Farina S, Baldonero E, Di Cristo V, et al. Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients. HIV Med 2013; 14:136-144.
73. Freiberg MS, Chang CC, Kuller LH, Skanderson M, Lowy E, Kraemer KL, et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173:614-622.
74. Fitch KV, Looby SE, Rope A, Eneh P, Hemphill L, Lee H, et al. Effects of aging and smoking on carotid intima-media thickness in HIV-infection. AIDS 2013; 27:49-57.
75. Galli L, Salpietro S, Pellicciotta G, Galliani A, Piatti P, Hasson H, et al. Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. Eur J Epidemiol 2012; 27:657-665.
76. Huber M, Ledergerber B, Sauter R, Young J, Fehr J, Cusini A, et al. Outcome of smoking cessation counselling of HIVpositive persons by HIV care physicians. HIV Med 2012; 13:387-397.
77. Jarrett OD, Wanke CA, Ruthazer R, Bica I, Isaac R, Knox TA. Metabolic syndrome predicts all-cause mortality in persons with human immunodeficiency virus. AIDS Patient Care STDS 2013; 27:266-271.
78. Koethe JR, Dee K, Bian A, Shintani A, Turner M, Bebawy S, et al. Circulating interleukin-6, soluble CD14, and other inflammation biomarker levels differ between obese and nonobese HIV-infected adults on antiretroviral therapy. AIDS Res Hum Retroviruses 2013; 29:1019-1025.
79. Madeddu G, Fois AG, Calia GM, Babudieri S, Soddu V, Becciu F, et al. Chronic obstructive pulmonary disease: an emerging comorbidity in HIV-infected patients in the HAART era? Infection 2013; 41:347-353.
80. Masiá M, Padilla S, Robledano C, Ramos JM, Gutiérrez F. Evaluation of endothelial function and subclinical atherosclerosis in association with hepatitis C virus in HIV-infected patients: a cross-sectional study. BMC Infect Dis 2011; 11:265.
81. Overton ET, Patel P, Mondy K, Bush T, Conley L, Rhame F, et al. Cystatin C and baseline renal function among HIVinfected persons in the SUN Study. AIDS Res Hum Retroviruses 2012; 28:148-155.
82. Pombo M, Olalla J, Del Arco A, De La Torre J, Urdiales D, Aguilar A, et al. Left ventricular hypertrophy detected by echocardiography in HIV-infected patients. Eur J Intern Med 2013; 24:558-561.
83. Quezada M, Martin-Carbonero L, Soriano V, Vispo E, Valencia E, Moreno V, et al. Prevalence and risk factors associated with pulmonary hypertension in HIV-infected patients on regular follow-up. AIDS 2012; 26:1387-1392.
84. Roca B, Bennasar M, Ferrero JA, del Monte MC, Resino E. Hepatitis C virus co-infection and sexual risk behaviour are associated with a high homocysteine serum level in HIV-infected patients. Swiss Med Wkly 2012; 141:w13323.
85. Shacham E, Lian M, Önen NF, Donovan M, Overton ET. Are neighborhood conditions associated with HIV management? HIV Med 2013; 14:624-632.
86. Shirley DK, Kesari RK, Glesby MJ. Factors associated with smoking in HIV-infected patients and potential barriers to cessation. AIDS Patient Care STDS 2013; 27:604-612.
87. Stewart DW, Jones GN, Minor KS. Smoking, depression, and gender in low-income African Americans with HIV/AIDS. Behav Med 2011; 37:77-80.
88. Vassallo M, Dunais B, Durant J, Carsenti-Dellamonica H, Harvey-Langton A, Cottalorda J, et al. Relevance of lipopolysaccharide levels in HIV-associated neurocognitive impairment: the Neuradapt study. J Neurovirol 2013; 19:376-382.
89. Yin MT, Kendall MA, Wu X, Tassiopoulos K, Hochberg M, Huang JS, et al. Fractures after antiretroviral initiation. AIDS 2012; 26:2175-2184.
90. Young B, Dao CN, Buchacz K, Baker R, Brooks JT, HIV Outpatient Study (HOPS) Investigators. Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis 2011; 52:1061-1068.
91. Beachler DC, Weber KM, Margolick JB, Strickler HD, Cranston RD, Burk RD, et al. Risk factors for oral HPV infection among a high prevalence population of HIV-positive and at-risk HIVnegative adults. Cancer Epidemiol Biomarkers Prev 2012; 21:122-133.
92. Kojic EM, Cu-Uvin S, Conley L, Bush T, Onyekwuluje J, Swan DC, et al. Human papillomavirus infection and cytologic abnormalities of the anus and cervix among HIV-infected women in the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (the SUN Study). Sex Transm Dis 2011; 38:253-259.
93. Konopnicki D, Manigart Y, Gilles C, Barlow P, de Marchin J, Feoli F, et al. Sustained viral suppression and higher CD4R T-cell count reduces the risk of persistent cervical high-risk human papillomavirus infection in HIV-positive women. J Infect Dis 2013; 207:1723-1729.
94. Siemieniuk RA, Krentz HB, Miller P, Woodman K, Ko K, Gill MJ. The clinical implications of high rates of intimate partner violence against HIV-positive women. J Acquir Immune Defic Syndr 2013; 64:32-38.
95. Stuardo V, Agust C, Godinez JM, Montoliu A, Torné A, Tarrats A, et al. Human papillomavirus infection in HIV-1 infected women in Catalonia (Spain): implications for prevention of cervical cancer. PLoS One 2012; 7:e47755.
96. Videla S, Darwich L, Canadas MP, Coll J, Pinol M, Garcá-Cuyás F, et al. Natural history of human papillomavirus infections involving anal, penile, and oral sites among HIV-positive men. Sex Transm Dis 2013; 40:3-10.
97. Schwartz LM, Castle PE, Follansbee S, Borgonovo S, Fetterman B, Tokugawa D, et al. Risk factors for anal HPV infection and anal precancer in HIV-infected men who have sex with men. J Infect Dis 2013; 208:1768-1775.
98. van der Snoek EM, van der Ende ME, den Hollander JC, Schutten M, Neumann HAM, van Doornum GJJ. Use of highly active antiretroviral therapy is associated with lower prevalence of anal intraepithelial neoplastic lesions and lower prevalence of human papillomavirus in HIV-infected men who have sex with men. Sex Transm Dis 2012; 39:495-500.
99. Wieland U, Silling S, Scola N, Potthoff A, Gambichler T, Brockmeyer NH, et al. Merkel cell polyomavirus infection in HIV-positive men. Arch Dermatol 2011; 147:401-406.
100. Marshall MM, Kirk GD, Caporaso NE, McCormack MC, Merlo CA, Hague JC, et al. Tobacco use and nicotine dependence among HIV-infected and uninfected injection drug users. Addict Behav 2011; 36:61-67.
101. Buchacz K, Baker RK, Palella FJ Jr, Shaw L, Patel P, Lichtenstein KA, et al. Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviraltreated HIV-infected adults in the US. Antivir Ther 2013; 18:65-75.
102. Esposito V, Chiodini P, Viglietti R, Parrella R, Parrella G, Maddaloni A, et al. Safety of fosamprenavir in a cohort of HIV-1-infected patients with co-morbidities. In Vivo 2011; 25:813-819.
103. Fong R, Cheng AC, Vujovic O, Hoy JF. Factors associated with virological failure in a cohort of combination antiretroviral therapy-treated patients managed at a tertiary referral centre. Sex Health 2013; 10:442-447.
104. Kim DJ, Westfall AO, Chamot E, Willig AL, Mugavero MJ, Ritchie C, et al. Multimorbidity patterns in HIV-infected patients: the role of obesity in chronic disease clustering. J Acquir Immune Defic Syndr 2012; 61:600-605.
105. Krishnan S, Schouten JT, Atkinson B, Brown T, Wohl D, McComsey GA, et al. Metabolic syndrome before and after initiation of antiretroviral therapy in treatment-naive HIVinfected individuals. J Acquir Immune Defic Syndr 2012; 61:381-389.
106. Winnock M, Bani-Sadr F, Pambrun E, Loko MA, Lascoux-Combe C, Garipuy D, et al. Prevalence of immunity to hepatitis viruses A and B in a large cohort of HIV/HCVcoinfected patients, and factors associated with HAV and HBV vaccination. Vaccine 2011; 29:8656-8660.
107. Sharma A, Cohen HW, Freeman R, Santoro N, Schoenbaum EE. Prospective evaluation of bone mineral density among middle-aged HIV-infected and uninfected women: association between methadone use and bone loss. Maturitas 2011; 70:295-301.
108. Chitsaz E, Meyer JP, Krishnan A, Springer SA, Marcus R, Zaller N, et al. Contribution of substance use disorders on HIV treatment outcomes and antiretroviral medication adherence among HIV-infected persons entering jail. AIDS Behav 2013; 17 (Suppl 2):S118-S127.
109. Devlin KN, Gongvatana A, Clark US, Chasman JD, Westbrook ML, Tashima KT, et al. Neurocognitive effects of HIV, hepatitis C, and substance use history. J Int Neuropsychol Soc 2012; 18:68-78.
110. Frontini M, Chotalia J, Spizale L, Onya W, Ruiz M, Clark RA. Sex and race effects on risk for selected outcomes among elderly HIV-infected patients. J Int Assoc Physicians AIDS Care 2012; 11:12-15.
111. Hutton HE, McCaul ME, Chander G, Jenckes MW, Nollen C, Sharp VL, et al. Alcohol use, anal sex, and other risky sexual behaviors among HIV-infected women and men. AIDS Behav 2013; 17:1694-1704.
112. Korthuis PT, Saha S, Chander G, McCarty D, Moore RD, Cohn JA, et al. Substance use and the quality of patient-provider communication in HIV clinics. AIDS Behav 2011; 15:832-841.
113. Martinez DA, Goggin K, Catley D, Gerkovich MM, Williams K, Wright J, et al. Do coping styles mediate the relationship between substance use and educational attainment and antiretroviral adherence? AIDS Behav 2012; 16:2319-2329.
114. Morano JP, Gibson BA, Altice FL. The burgeoning HIV/HCV syndemic in the urban Northeast: HCV, HIV, and HIV/HCV coinfection in an urban setting. PLoS One 2013; 8:e64321.
115. Roux P, Cohen J, Lascoux-Combe C, Sogni P, Winnock M, Salmon-Ceron D, et al. Determinants of the underreporting of alcohol consumption by HIV/HCV co-infected patients during face-to-face medical interviews: the role of the physician. Drug Alcohol Depend 2011; 116:228-232.
116. Shacham E, Agbebi A, Stamm K, Overton ET. Alcohol consumption is associated with poor health in HIV clinic patient population: a behavioral surveillance study. AIDS Behav 2011; 15:209-213.
117. Surah S, Kieran J, O'Dea S, Shiel C, Raffee S, Mulcahy F, et al. Use of the Alcohol Use Disorders Identification Test (AUDIT) to determine the prevalence of alcohol misuse among HIV-infected individuals. Int J STD AIDS 2013; 24:517-521.
118. Yoon JC, Crane PK, Ciechanowski PS, Harrington RD, Kitahata MM, Crane HM. Somatic symptoms and the association between hepatitis C infection and depression in HIV-infected patients. AIDS Care 2011; 23:1208-1218.
119. Crystal H, Kleyman I, Anastos K, Lazar J, Cohen M, Liu C, et al. Effects of hepatitis C and HIV on cognition in women: data from the Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2012; 59:149-154.
120. McGinnis KA, Justice AC, Kraemer KL, Saitz R, Bryant KJ, Fiellin DA. Comparing alcohol screening measures among HIV-infected and-uninfected men. Alcohol Clin Exp Res 2013; 37:435-442.
121. Skeer MR, Mimiaga MJ, Mayer KH, O'Cleirigh C, Covahey C, Safren SA. Patterns of substance use among a large urban cohort of HIV-infected men who have sex with men in primary care. AIDS Behav 2012; 16:676-689.
122. Gangcuangco LM, Chow DC, Liang CY, Nakamoto BK, Umaki TM, Kallianpur KJ, et al. Predictors of 25-hydroxyvitamin D levels in HIV-infected patients in Hawai'i. Hawaii J Med Public Health 2013; 72:197-201.
123. Patel N, Veve M, Kwon S, McNutt LA, Fish D, Miller CD. Frequency of electrocardiogram testing among HIV-infected patients at risk for medication-induced QTc prolongation. HIV Med 2013; 14:463-471.
124. Bauer LO. Interactive effects of HIV/AIDS, body mass, and substance abuse on the frontal brain: a P300 study. Psychiatry Res 2011; 185:232-237.
125. Chung RT, Umbleja T, Chen JY, Andersen JW, Butt AA, Sherman KE, et al. Extended therapy with pegylated interferon and weight-based ribavirin for HCV-HIV coinfected patients. HIV Clin Trials 2012; 13:70-82.
126. Blashill AJ, Mayer KH, Crane HM, Grasso C, Safren SA. Body mass index, immune status, and virological control in HIVinfected men who have sex with men. J Int Assoc Provid AIDS Care 2013; 12:319-324.
127. Salter ML, Lau B, Mehta SH, Go VF, Leng S, Kirk GD. Correlates of elevated interleukin-6 and C-reactive protein in persons with or at high risk for HCV and HIV infections. J Acquir Immune Defic Syndr 2013; 64:488-495.
128. Garbuglia AR, Piselli P, Lapa D, Sias C, Del Nonno F, Baiocchini A, et al. Frequency and multiplicity of human papillomavirus infection in HIV-1 positive women in Italy. J Clin Virol 2012; 54:141-146.
129. Kang M, Cu-Uvin S. Association of HIV viral load and CD4 cell count with human papillomavirus detection and clearance in HIV-infected women initiating highly active antiretroviral therapy. HIV Med 2012; 13:372-378.
130. Beachler DC, D'Souza G, Sugar EA, Xiao W, Gillison ML. Natural history of anal vs oral HPV infection in HIV-infected men and women. J Infect Dis 2013; 208:330-339.
131. Del Mistro A, Baboci L, Frayle-Salamanca H, Trevisan R, Bergamo E, Lignitto L, et al. Oral human papillomavirus and human herpesvirus-8 infections among human immunodeficiency virus type 1-infected men and women in Italy. Sex Transm Dis 2012; 39:894-898.
132. Steinau M, Reddy D, Sumbry A, Reznik D, Gunthel CJ, Del Rio C, et al. Oral sampling and human papillomavirus genotyping in HIV-infected patients. J Oral Pathol Med 2012; 41:288-291.
133. Parisi SG, Cruciani M, Scaggiante R, Boldrin C, Andreis S, Dal Bello F, et al. Anal and oral human papillomavirus (HPV) infection in HIV-infected subjects in northern Italy: a longitudinal cohort study among men who have sex with men. BMC Infect Dis 2011; 11:150.
134. Read TR, Hocking JS, Vodstrcil LA, Tabrizi SN, McCullough MJ, Grulich AE, et al. Oral human papillomavirus in men having sex with men: risk-factors and sampling. PLoS One 2012; 7:e49324.
135. Cranston RD, Murphy R, Weiss RE, Da Costa M, Palefsky J, Shoptaw S, et al. Anal human papillomavirus infection in a street-based sample of drug using HIV-positive men. Int J STD AIDS 2012; 23:195-200.
136. Sahasrabuddhe VV, Castle PE, Follansbee S, Borgonovo S, Tokugawa D, Schwartz LM, et al. Human papillomavirus genotype attribution and estimation of preventable fraction of anal intraepithelial neoplasia cases among HIV-infected men who have sex with men. J Infect Dis 2013; 207:392-401.
137. Torres M, González C, del Romero J, Viciana P, Ocampo A, Rodríguez-Fortúnez P, et al. Anal human papillomavirus genotype distribution in HIV-infected men who have sex with men by geographical origin, age, and cytological status in a Spanish cohort. J Clin Microbiol 2013; 51:3512-3520.
138. Goldstone SE, Lowe B, Rothmann T, Nazarenko I. Evaluation of the hybrid capture 2 assay for detecting anal high-grade dysplasia. Int J Cancer 2012; 131:1641-1648.
139. Swedish KA, Lee EQ, Goldstone SE. The changing picture of high-grade anal intraepithelial neoplasia in men who have sex with men: the effects of 10 years of experience performing high-resolution anoscopy. Dis Colon Rectum 2011; 54:1003-1007.
140. Angeli E, Mainini A, Meraviglia P, Schiavini M, Ricci E, Giorgi R, et al. Eligibility and feasibility of the treatment of chronic hepatitis C in a cohort of Italian HIV-positive patients at a single HIV reference center. AIDS Patient Care STDS 2011; 25:295-301.
141. Bickel M, Marben W, Betz C, Khaykin P, Stephan C, Gute P, et al. End-stage renal disease and dialysis in HIV-positive patients: observations from a long-term cohort study with a follow-up of 22 years. HIV Med 2013; 14:127-135.
142. Branch AD, Van Natta ML, Vachon ML, Dieterich DT, Meinert CL, Jabs DA, et al. Mortality in hepatitis C virusinfected patients with a diagnosis of AIDS in the era of combination antiretroviral therapy. Clin Infect Dis 2012; 55:137-144.
143. Di Biagio A, Rosso R, Vitale F, Cardinale F, Sormani MP, Secondo G, et al. Risk factors for chronic kidney disease among human immunodeficiency virus-infected patients: a European case control study. Clin Nephrol 2011; 75:518-523.
144. Di Lello FA, Macás J, Cifuentes CC, Vargas J, Palomares JC, Pineda JA. Low prevalence of occult HBV infection among HIV-infected patients in Southern Spain. Enferm Infecc Microbiol Clin 2012; 30:312-314.
145. Grebely J, Raffa JD, Lai C, Kerr T, Fischer B, Krajden M, et al. Impact of hepatitis C virus infection on all-cause and liverrelated mortality in a large community-based cohort of inner city residents. J Viral Hepat 2011; 18:32-41.
146. Jernigan TL, Archibald SL, Fennema-Notestine C, Taylor MJ, Theilmann RJ, Julaton MD, et al. Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol 2011; 17:248-257.
147. Kim JH, Psevdos G Jr, Sharp V. Five-year review of HIVhepatitis B virus (HBV) co-infected patients in a New York City AIDS center. J Korean Med Sci 2012; 27:830-833.
148. Linas BP, Wang B, Smurzynski M, Losina E, Bosch RJ, Schackman BR, et al. The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort. J Viral Hepat 2011; 18:506-512.
149. Marcellin F, Lacombe K, Fugon L, Molina JM, Bonnard P, Miailhes P, et al. Correlates of poor perceived health among individuals living with HIV and HBV chronic infections: a longitudinal assessment. AIDS Care 2011; 23:501-507.
150. Pensieroso S, Galli L, Nozza S, Ruffin N, Castagna A, Tambussi G, et al. B-cell subset alterations and correlated factors in HIV-1 infection. AIDS 2013; 27:1209-1217.
151. Pérez Cachafeiro S, Caro-Murillo AM, Berenguer J, Segura F, Gutiérrez F, Vidal F, et al. Association of patients' geographic origins with viral hepatitis co-infection patterns, Spain. Emerg Infect Dis 2011; 17:1116-1119.
152. Raboud J, Anema A, Su D, Klein MB, Zakaryan A, Swan T, et al. Relationship of chronic hepatitis C infection to rates of AIDSdefining illnesses in a Canadian cohort of HIV seropositive individuals receiving highly active antiretroviral therapy. HIV Clin Trials 2012; 13:90-102.
153. Reiberger T, Obermeier M, Payer BA, Baumgarten A, Weitner L, Moll A, et al. Considerable under-treatment of chronic HCV infection in HIV patients despite acceptable sustained virological response rates in a real-life setting. Antivir Ther 2011; 16:815-824.
154. Reuter S, Oette M, Wilhelm FC, Beggel B, Kaiser R, Balduin M, et al. Prevalence and characteristics of hepatitis B and C virus infections in treatment-naive HIV-infected patients. Med Microbiol Immunol 2011; 200:39-49.
155. Sassoon SA, Rosenbloom MJ, Fama R, Sullivan EV, Pfefferbaum A. Selective neurocognitive deficits and poor life functioning are associated with significant depressive symptoms in alcoholism-HIV infection comorbidity. Psychiatry Res 2012; 199:102-110.
156. Speers S, Klevens RM, Vonderwahl C, Bryant T, Daniloff E, Capizzi J, et al. Electronic matching of HIV/AIDS and hepatitis C surveillance registries in three states. Public Health Rep 2011; 126:344-348.
157. Weimer LE, Fragola V, Floridia M, Guaraldi G, Ladisa N, Francisci D, et al. Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. J Antimicrob Chemother 2013; 68:193-199.
158. Witteck A, Schmid P, Hensel-Koch K, Thurnheer MC, Bruggmann P, Vernazza P, et al. Management of hepatitis C virus (HCV) infection in drug substitution programs. Swiss Med Wkly 2011; 141:w13193.
159. Floridia M, Mastroiacovo P, Tamburrini E, Tibaldi C, Todros T, Crepaldi A, et al. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011. BJOG 2013; 120:1466-1475.
160. Barfod TS, Omland LH, Katzenstein TL. Incidence and characteristics of sexually transmitted acute hepatitis C virus infection among HIV-positive men who have sex with men in Copenhagen, Denmark during four years (2006-2009): a retrospective cohort study. Scand J Infect Dis 2011; 43:145-148.
161. Gamage DG, Read TR, Bradshaw CS, Hocking JS, Howley K, Chen MY, et al. Incidence of hepatitis-C among HIV infectedmen who have sex with men (MSM) attending a sexual health service: a cohort study. BMC Infect Dis 2011; 11:39.
162. Hoover KW, Butler M, Workowski KA, Follansbee S, Gratzer B, Hare CB, et al. Low rates of hepatitis screening and vaccination of HIV-infected MSM in HIV clinics. Sex Transm Dis 2012; 39:349-353.
163. Matser A, Vanhommerig J, Schim van der Loeff MF, Geskus RB, de Vries HJC, Prins JM, et al. HIV-infected men who have sex with men who identify themselves as belonging to subcultures are at increased risk for hepatitis C infection. PLoS One 2013; 8:e57740.
164. van der Helm JJ, Prins M, del Amo J, Bucher HC, Chene G, Dorrucci M, et al. The hepatitis C epidemic among HIVpositive MSM: incidence estimates from 1990 to 2007. AIDS 2011; 25:1083-1091.
165. Bayón C, Ribera E, Cabrero E, Griffa L, Burgos A. Prevalence of depressive and other central nervous system symptoms in HIV-infected patients treated with HAART in Spain. J Int Assoc Physicians AIDS Care 2012; 11:321-328.
166. Guaraldi G, Lonardo A, Ballestri S, Zona S, Stentarelli C, Orlando G, et al. Human immunodeficiency virus is the major determinant of steatosis and hepatitis C virus of insulin resistance in virus-associated fatty liver disease. Arch Med Res 2011; 42:690-697.
167. Labarga P, Soriano V, Caruz A, Poveda E, Di Lello FA, Hernandez-Quero J, et al. Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-coinfected patients. AIDS 2011; 25:761-766.
168. Rabkin JG, McElhiney MC, Rabkin R. Modafinil and armodafinil treatment for fatigue for HIV-positive patients with and without chronic hepatitis C. Int J STD AIDS 2011; 22:95-101.
169. Suárez-Zarracina T, Valle-Garay E, Collazos J, Montes AH, Cárcaba V, Carton JA, et al. Didanosine (ddI) associates with increased liver fibrosis in adult HIV-HCV coinfected patients. J Viral Hepat 2012; 19:685-693.
170. Treviño A, Soriano V, Rodríguez C, Arredondo M, Rivas P, Herrero-Mendoza D, et al. Changing rate of non-B subtypes and coinfection with hepatitis B/C viruses in newly diagnosed HIV type 1 individuals in Spain. AIDS Res Hum Retroviruses 2011; 27:633-638.
171. Tsui JI, Cheng DM, Libman H, Bridden C, Samet J. Hepatitis C virus infection is associated with painful symptoms in HIVinfected adults. AIDS Care 2012; 24:820-827.
172. Vermehren J, Vermehren A, Mueller A, Carlebach A, Lutz T, Gute P, et al. Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers. BMC Gastroenterol 2012; 12:27.
173. Raymond HF, Chu P, Nieves-Rivera I, Louie B, McFarland W, Pandori M. Hepatitis C infection among men who have sex with men, San Francisco, 2011. Sex Transm Dis 2012; 39:985-986.
174. Chun HM, Roediger MP, Hullsiek KH, Thio CL, Agan BK, Bradley WP, et al. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis 2012; 205:185-193.
175. Coffin CS, Osiowy C, Myers RP, Gill MJ. Virology and clinical sequelae of long-term antiviral therapy in a North American cohort of hepatitis B virus (HBV)/human immunodeficiency virus type 1 (HIV-1) co-infected patients. J Clin Virol 2013; 57:103-108.
176. Clifford GM, Gonçalves MA, Franceschi S, HPV and HIV Study Group. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 2006; 20:2337-2344.
177. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011; 103:753-762.
178. Torian L, Chen M, Rhodes P, Hall HI. HIV surveillance-United States, 1981-2008. MMWR Morb Mortal Wkly Rep 2011; 60:689-693.
179. Boodram B, PlankeyMW, Cox C, Tien PC, Cohen MH, Anastos K, et al. Prevalence and correlates of elevated body mass index among HIV-positive and HIV-negative women in the Women's Interagency HIV Study. AIDS Patient Care STDS 2009; 23:1009-1016.
180. Crum-Cianflone N, Tejidor R, Medina S, Barahona I, Ganesan A. Obesity among patients with HIV: the latest epidemic. AIDS Patient Care STDS 2008; 22:925-930.
181. Palefsky J. Biology of HPV in HIV infection. Adv Dent Res 2006; 19:99-105.
182. Lakey W, Yang LY, Yancy W, Chow SC, Hicks C. Short communication: from wasting to obesity: initial antiretroviral therapy and weight gain in HIV-infected persons. AIDS Res Hum Retroviruses 2013; 29:435-440.
183. Drach L, Holbert T, Maher J, Fox V, Schubert S, Saddler LC. Integrating smoking cessation into HIV care. AIDS Patient Care STDS 2010; 24:139-140.
184. Lifson AR, Lando HA. Smoking and HIV: prevalence, health risks, and cessation strategies. Curr HIV/AIDS Rep 2012; 9:223-230.
185. Toft L, Storgaard M, Müller M, Sehr P, Bonde J, Tolstrup M, et al. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis 2014; 209:1165-1173.
186. Kojic EM, Kang M, Cespedes MS, Umbleja T, Godfrey C, Allen RT, et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis 2014; 59:127-135.
187. Wilkin T, Lee JY, Lensing SY, Stier EA, Goldstone SE, Berry JM, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010; 202:1246-1253.
188. Kahn JA, Xu J, Kapogiannis BG, Rudy B, Gonin R, Liu N, et al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis 2013; 57:735-744.
189. Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207.
190. Whitaker JA, Rouphael NG, Edupuganti S, Lai L, Mulligan MJ. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis 2012; 12:966-976.
191. Osinusi A, Townsend K, Kohli A,Nelson A, Seamon C,Meissner EG, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients withHCV genotype 1 and HIV co-infection. JAMA 2015; 313:1232-1239.
192. Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA2015; 313:1223-1231.
193. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, 2014. http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. [Accessed 25 February 2015]
194. Cui Q, Robinson L, Elston D, Smaill F, Cohen J, Quan C, et al. Safety and tolerability of varenicline tartrate (Champix W/Chantix 1) for smoking cessation in HIV-infected subjects: a pilot open-label study. AIDS Patient Care STDS 2012; 26:12-19.
195. Park J, Vousden M, Brittain C, McConn DJ, Iavarone L, Ascher J, et al. Dose-related reduction in bupropion plasma concentrations by ritonavir. J Clin Pharmacol 2010; 50:1180-1187.
196. American Association for the Study of Liver Diseases, Infectious Diseases Society of America, International Antiviral Society. Recommendations for testing, managing, and treating hepatitis C, 2014. http://www.hcvguidelines.org/full-reportview. [Accessed 25 February 2015]
197. Firnhaber C, Wilkin T. Human papillomavirus vaccines: where do they fit in HIV-infected individuals? Curr HIV/AIDS Rep 2012; 9:278-286.
198. Heard I. Human papillomavirus, cancer and vaccination. Curr Opin HIV AIDS 2011; 6:297-302.
199. Widdice LE, Bernstein DI, Leonard AC, Marsolo KA, Kahn JA. Adherence to the HPV vaccine dosing intervals and factors associated with completion of 3 doses. Pediatrics 2011; 127:77-84.